KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) EPS (Basic): 2014-2024

Historic EPS (Basic) for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$4.34.

  • CRISPR Therapeutics AG's EPS (Basic) fell 15.84% to -$1.17 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.57, marking a year-over-year decrease of 98.93%. This contributed to the annual value of -$4.34 for FY2024, which is 123.71% down from last year.
  • As of FY2024, CRISPR Therapeutics AG's EPS (Basic) stood at -$4.34, which was down 123.71% from -$1.94 recorded in FY2023.
  • In the past 5 years, CRISPR Therapeutics AG's EPS (Basic) registered a high of $4.97 during FY2021, and its lowest value of -$8.36 during FY2022.
  • In the last 3 years, CRISPR Therapeutics AG's EPS (Basic) had a median value of -$4.34 in 2024 and averaged -$4.88.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's EPS (Basic) slumped by 530.08% in 2020, and later soared by 193.95% in 2021.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's EPS (Basic) stood at -$5.29 in 2020, then soared by 193.95% to $4.97 in 2021, then slumped by 268.21% to -$8.36 in 2022, then soared by 76.79% to -$1.94 in 2023, then slumped by 123.71% to -$4.34 in 2024.